NKGen Biotech Inc Ordinary Shares NKGN 深 滬
等待開盤 09-20 09:30:00 美东时间
0.4275
-0.050
-10.45%
華盛通- 最 高0.491
- 今 開0.48
- 成交量 60.88万股
- 最 低 0.4275
- 昨 收 0.4774
- 總市值 1511.74万
- 52周最高 6.70
- 市盈率 靜 --
- 換手率 1.72%
- 52周最低 0.4275
- 委 比 62.97%
- 總股本 3536.24万
- 歷史最高 6.70
- 量 比 0.62
- 振 幅 13.30%
- 歷史最低 0.4275
- 每 手 1
- 風險率 1.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Intel Corporation (NASDAQ:INTC) rose sharply in today's pre-market tr...
09-17 17:48
NKGen Biotech Expands Agreement Terms and Restructures COO Role
NKGen Biotech ( ($NKGN) ) has provided an update. NKGen Biotech, Inc. has amend...
09-12 05:47
NKGen Biotech Faces Nasdaq Compliance Challenges
An announcement from NKGen Biotech (NKGN) is now available. NKGen Biotech, Inc....
08-23 05:00
NKGen Biotech receives non-compliance notification from Nasdaq
NKGen Biotech (NASDAQ:NKGN) received a standard notice from Nasdaq that the company is not in compliance with Nasdaq Listing Rule because it had not timely filed its quarterly report on Form 10-Q. The...
08-23 04:50
NKGen Biotech COO Pierre Gagnon Steps Down, Remains Advisor
NKGen Biotech (NKGN) has issued an announcement. Pierre Gagnon has stepped down...
08-22 04:27
Market-Moving News for July 18th
NKGN: 88% | NKGen Biotech Will Present New Biomarker Data On SNK01 In Alzheimer's Disease During A Poster Presentation At The Upcoming Alzheimer's Association International Conference From July 28 – August
07-18 20:28
SPAC大佬旗下又有“壳公司”申请上市：Graf Global(GRAF.US)拟IPO筹资2亿美元
SPAC资深人士James Graf领导的空白支票公司Graf Global周五向SEC提交了IPO申请。
06-03 14:50
Dow Falls Over 150 Points; Sohu Posts Q1 Loss
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index fa...
05-21 02:31
Nasdaq Surges 100 Points; Wix.com Shares Jump Following Q1 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gai...
05-21 00:03
Why NKGen Biotech Stock Is Moving Higher Monday
NKGen Biotech shares are trading higher Monday after the company's SNK01 NK Cell Therapy was cleared to begin a Phase 2 trial in Alzheimer's disease.
05-20 21:17
